Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Phase 2 Terminated 6 enrolled Seoul National University Hospital Asan Medical Center · collab Samsung Medical Center · collab Seoul National University Bundang Hospital · collab Severance Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

Alveolar soft part sarcoma (ASPS), a rare subset of STS (\<1%) harbors t(X;17)(p11;q25) translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high expression of angiogenic factors, sunitinib and cediranib produced overall response rates of 55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS.

Timeline

Start: 2014-04
Primary completion: 2016-09
Completion: 2017-11

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual rate”

Publications

Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, Kim DW, Heo DS. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. Oncologist. 2019 Jan;24(1):20-e29. doi: 10.1634/theoncologist.2018-0464. Epub 2018 Sep 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pazopanib	Small molecule	800 mg	Oral